Gloss and Vickrey conducted a Cochrane systematic review of the use of CBD in the treatment of epilepsy (11). Their methodology included only those trials that were randomized and controlled and excluded case series, case reports, and expert opinion. They were able to identify only 4 randomized controlled studies reported in the literature, and they included a letter to the editor and an abstract. The total number of subjects enrolled in these studies was 48 (11–14). While only four studies and a letter to the editor were in the actual analysis, the authors included a complete reference listing of all articles reviewed for inclusion.
The science behind CBD is in the relatively early stages. As a cannabinoid, we know that CBD interacts with receptors in your endocannabinoid system. The endocannabinoid system is integrated throughout your body — and this widespread, whole-body interaction creates a broad range of effects. Hence, the long list of possible benefits. We may still be in the early stages of discovery, but there’s plenty of scientific studies and anecdotal evidence that CBD provides relief for an array of ailments. Here’s a non-exhaustive list of some potential benefits of CBD oil:
That leaves those touting CBD’s effectiveness pointing primarily to research in mice and petri dishes. There, CBD (sometimes combined with small amounts of THC) has shown promise for helping pain, neurological conditions like anxiety and PTSD, and the immune system—and therefore potentially arthritis, diabetes, multiple sclerosis, cancer, and more.
The reason so many people are interested in cannabis products that don’t make them high, proponents say, is that CBD helps with everything from pain and nausea to rheumatoid arthritis, cancer, Crohn’s disease, and dementia. CBD is anti-inflammatory, anti-anxiety, antibacterial, immunosuppressive, and more, says Joseph Cohen, DO, a cannabis doctor in Boulder, CO.
Studies have demonstrated that CBD has a low affinity for the CB1 receptors, but even at low concentrations, CBD decreases G-protein activity (3). CB1 receptors are expressed on many glutamatergic synapses that have been implicated in seizure threshold modulation. CBD may act at CB1 receptors to inhibit glutamate release (4). Studies have shown changes in the expression of CB1 receptors during epileptogenesis and after recurrent seizures (5). CB1 receptor expression is upregulated at GABAergic synapses and shown to be downregulated at glutamatergic synapses in epilepsy, contributing to lowering seizure thresholds.
This is the second time Moon Mother Hemp Company has placed among the top five brands on our ranking. The Colorado-based company, which was founded about a year ago, sets the bar very high for quality (including USDA-certified organic hemp) without charging the moon for its products. Their tinctures taste so good, you may be sad you don’t need more.